Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) is the deadliest infectious
disease and the associated global threat has worsened with the emergence of drug …

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB
epidemic. Recent efforts have focused on the development of whole-cell screening assays …

Tuberculosis (TB), an infectious disease caused by the bacterium Mycobacterium
tuberculosis (Mtb), has burdened vulnerable populations in modern day societies for …

Inclusion of pyrazinamide (PZA) in the tuberculosis (TB) drug regimen during the 1970s
enabled a reduction in treatment duration from 12 to 6 months. PZA has this remarkable …

Pyrazinamide has been a mainstay in the multidrug regimens used to treat tuberculosis. It is
active against the persistent, non-replicating mycobacteria responsible for the protracted …

Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of
tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease …

Previously, we showed that a major in vitro and in vivo mechanism of resistance to
pyrazinoic acid (POA), the bioactive component of the critical tuberculosis (TB) prodrug …

TB continues to be a leading health threat despite the availability of powerful anti-TB drugs.
We report herein the design and synthesis of various hybrid molecules comprising pyrazine …

After decades of relative inactivity, a large increase in efforts to discover antitubercular
therapeutics has brought insights into the biology of Mycobacterium tuberculosis (Mtb) and …

Transition bias, an overabundance of transitions relative to transversions, has been widely
reported among studies of the rates and spectra of spontaneous mutations. However …